Pfizer: licensing agreement outside China with 3SBio

Published: 2025-05-20 03:56:21 ET PFE

Published on 05/20/2025 at 03:56

Pfizer announced Monday evening an agreement with Chinese group 3SBio, granting the US company an exclusive license for the development, manufacture and commercialization, outside China, of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF.Currently undergoing several clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer and gynecological tumors, SSGJ-707 has shown promising initial efficacy and safety data.Under the agreement, 3SBio will receive an initial payment of $1.25bn from Pfizer and will be eligible for milestone payments of up to $4.8bn, as well as double-digit tiered royalties on sales of SSGJ-707, if approved.The transaction is expected to close in the third quarter, subject to customary approvals and other conditions. Pfizer will then make a $100 million equity investment in 3SBio, subject to agreement between the parties.Copyright (c) 2025 CercleFinance.com. All rights reserved.